SUDV vaccine candidates that have or are rapidly progressing to human trials as of 15 November 2022
| Vaccine name | Studies conducted | Lead institution |
| cAd3-EBO S (VRC-EBOADC086-00-VP | Phase I clinical trials in Uganda and USA, completed Planning phase II trial | Sabin Vaccine Institute (NIAID) |
| ChAdOx1 biEBOV | Phase I clinical trials in the UK and Tanzania (currently recruiting) | University of Oxford |
| rVSV SUDV GP | Preclinical phase, rapidly preparing for phase I trial and efficacy studies | MSD |
| Ad26.ZEBOV, MVA-BN-Filo | Phase III clinical trial in Sierra Leone, completed Vaccine approved by the European Medicines Agency (EMA) | Johnson & Johnson |
*The Johnson & Johnson vaccine is a two-dose regimen with the second dose providing protection against SUDV. The second dose is administered after 56 days of the first dose.1
EMA, European Medicines Agency; MSD, Merck; NIAID, National Institute of Allergy and Infectious Diseases; SUDV, Sudan ebolavirus.